Abstract

Background

Our aim was to measure the impact of two cycles of standard chemotherapy on tumoural neoangiogenesis by [18F] fluorine arginine-glycine-aspartic (RGD-K5) positron emission tomography–computed tomography (PET) on patients presenting with lymphoma. Nineteen patients at Rouen’s Henri Becquerel Cancer Centre were prospectively included. Fluorodeoxyglucose (FDG) and RGD-K5 PET were performed before (C0) and after (C2) two cycles of chemotherapy. End-of-treatment FDG PET was performed for final evaluation. Maximum standardised uptake value (SUVmax), SUVmean, Metabolic Tumour Volume (MTV) and Angiogenic Tumour Volume (ATV) were measured for all lesions. RGD SUVmax and SUVmean were also analysed in 13 normal organs at C0 and C2. The patient’s treatment response was considered using the Deauville score (DS) at the end of FDG PET treatment (DS 1–3 were considered responders, and 4 and 5 non-responders).

Results

Eighteen patients had both C0 FDG and RGD PET. Twelve patients had both C2 FDG and RGD, completed the treatment protocol and were included in end-of-treatment analysis. No statistical difference was found in RGD uptake of normal organs before and after chemotherapy for SUVmax and SUVmean. On C0 RGD, apart from classical Hodgkin lymphoma (cHL; n = 5) and grey zone lymphoma (GZL; n = 1), other lymphoma sub-types (n = 12) had low RGD uptake (p < 0.001). Regarding FDG, there was no significant difference for SUVmax, SUVmean and MTV at C0 and C2 between patients with cHL and non-Hodgkin lymphoma (NHL). At C2 RGD, non-responders had higher SUVmax and SUVmean compared to responders (p < 0.001). There was no significant difference in RGD ATV between responders and non-responders.

Conclusions

Our study showed significant higher initial RGD uptake in patients presenting with cHL and GZL compared to NHL. Non-responder also had higher post-chemotherapy RGD uptake compared to responders. Issues raised by RGD uptake, particularly in cHL, are yet to be explored and need to be confirmed in a larger population.

Details

Title
Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence
Author
Tonnelet, David 1   VIAFID ORCID Logo  ; Pierre, Bohn M D 1 ; Becker, Stephanie 1 ; Decazes Pierre 1 ; Camus, Vincent 2 ; Thureau Sebastien 3 ; Tilly Hervé 2 ; Jardin Fabrice 2 ; Vera, Pierre 1 

1  Rouen University Hospital & QuantIF-LITIS, University of Rouen, Department of Nuclear Medicine, Henri Becquerel Cancer Center, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034) 
2  Rouen University Hospital & QuantIF-LITIS, University of Rouen, Inserm U1245 and Department of Hematology, Henri Becquerel Cancer Center, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034) 
3  Rouen University Hospital & QuantIF-LITIS, University of Rouen, Department of Nuclear Medicine, Henri Becquerel Cancer Center, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034); Rouen University Hospital & QuantIF-LITIS, University of Rouen, Depatment of Radiotherapy Henri Becquerel Cancer Center, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034) 
Publication year
2021
Publication date
Apr 2021
Publisher
Springer Nature B.V.
e-ISSN
2191219X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s13550-021-00776-9
ProQuest document ID
2511579868
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.